[⁶⁸Ga]‑DOTA‑conjugated somatostatin receptor‑targeting peptide PET for the differentiation between meningioma and glioblastoma: A case report and review of the literature.

ABSTRACT: [⁶⁸Ga]-tetraazacyclododecanetetraacetic acid (DOTA)-conjugated positron emission tomography (PET) is widely used to identify meningiomas due to their high expression of somatostatin receptor type 2 (SSTR2). However, recent evidence suggests that this tracer may also show uptake in high-grade gliomas, raising concerns about its diagnostic specificity. The current study presents a challenging case of a 56-year-old man who was initially diagnosed with a right temporal glioblastoma. Follow-up imaging revealed a local recurrence and a new extra-axial lesion suggestive of meningioma on magnetic resonance imaging and [⁶⁸Ga]-DOTA-octreotide (DOTATOC) PET. Unexpectedly, histopathological analysis following resection confirmed both lesions as glioblastomas, indicating that SSTR

SUBMITTER: Rauschenbach L 

PROVIDER: S-EPMC11883336 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature